We are dedicated to developing a safe and effective DNA vaccine to protect against COVID-19 using our Fusogenix PLV platform.
On April 15, 2021, the first recruits (healthy adults aged 18-84 years of age) were dosed to start the Phase 1 trial of Entos’ made-in-Canada COVID-19 DNA vaccine, Covigenix VAX-001, at the Canadian Center for Vaccinology (CCfV) in Halifax, Nova Scotia.
Like the globally approved mRNA vaccines, Entos’ DNA vaccine delivers the information needed for our cells to make the spike protein to stimulate a protective immune response against SARS-CoV-2.
We believe that Entos’ Covigenix DNA vaccine offers the advantages of stability at fridge and room temperatures and ease of upscaling and manufacturing millions of doses.
“We need to get 16 billion doses worldwide to beat this pandemic, and we believe DNA is the perfect way to approach that,” said John Lewis, CEO Entos Pharmaceuticals.
Entos' Fusogenix PLV technology is ideal for the delivery of next generation nucleic acid-based therapies.
Unlike conventional lipid-based delivery systems, Fusogenix PLVs are well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique PLV formulations to effectively deliver a wide range of nucleic acid therapies, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.
Fusogenix PLVs are widely biodistributed across all organs and tissues.
Due to the unique biophysical and chemical properties of Fusogenix PLVs, a wide variety of extra-hepatic tissues can be effectively targeted at therapeutic doses. Entos has developed a panel of Fusogenix PLV formulations to accurately target specific tissues.
The Fusogenix PLV platform uses a novel fusion mechanism to deliver the payload directly inside cells.
Our proprietary FAST (Fusion-Associated Small Transmembrane) protein technology enables fusion of the proteo-lipid vehicle with the plasma membrane of target cells. Nucleic acid payloads are delivered intact into the cytoplasm for immediate use as a therapeutic agent.